- Home
- ACVA vs MIRM Comparison
ACVA vs MIRM Comparison
Compare ACVA & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACVA
- MIRM
- Stock Information
- Founded
- ACVA 2014
- MIRM 2018
- Country
- ACVA United States
- MIRM United States
- Employees
- ACVA N/A
- MIRM N/A
- Industry
- ACVA Business Services
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- ACVA Consumer Discretionary
- MIRM Health Care
- Exchange
- ACVA Nasdaq
- MIRM Nasdaq
- Market Cap
- ACVA 2.7B
- MIRM 2.5B
- IPO Year
- ACVA 2021
- MIRM 2019
- Fundamental
- Price
- ACVA $13.75
- MIRM $52.49
- Analyst Decision
- ACVA Strong Buy
- MIRM Strong Buy
- Analyst Count
- ACVA 11
- MIRM 9
- Target Price
- ACVA $22.27
- MIRM $66.22
- AVG Volume (30 Days)
- ACVA 1.6M
- MIRM 347.4K
- Earning Date
- ACVA 08-11-2025
- MIRM 08-11-2025
- Dividend Yield
- ACVA N/A
- MIRM N/A
- EPS Growth
- ACVA N/A
- MIRM N/A
- EPS
- ACVA N/A
- MIRM N/A
- Revenue
- ACVA $674,164,000.00
- MIRM $379,251,000.00
- Revenue This Year
- ACVA $24.03
- MIRM $36.76
- Revenue Next Year
- ACVA $21.95
- MIRM $17.48
- P/E Ratio
- ACVA N/A
- MIRM N/A
- Revenue Growth
- ACVA 32.89
- MIRM 69.31
- 52 Week Low
- ACVA $11.88
- MIRM $36.20
- 52 Week High
- ACVA $23.46
- MIRM $54.78
- Technical
- Relative Strength Index (RSI)
- ACVA 32.21
- MIRM 53.64
- Support Level
- ACVA $13.98
- MIRM $50.92
- Resistance Level
- ACVA $15.32
- MIRM $52.63
- Average True Range (ATR)
- ACVA 0.50
- MIRM 1.51
- MACD
- ACVA -0.14
- MIRM -0.32
- Stochastic Oscillator
- ACVA 9.68
- MIRM 23.08
About ACVA ACV Auctions Inc.
ACV Auctions Inc is a mobile platform for wholesale car auctions. The company provides a digital marketplace for wholesale vehicle transactions and data services that offer transparent and accurate vehicle information for customers.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.